All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2017-07-31T08:00:23.000Z

FDA approves the Investigational New Drug Application for PCM-075 for the treatment of AML

Jul 31, 2017
Share:

Bookmark this article

On 27th July 2017, the U.S. Food and Drug Administration (FDA) accepted the Investigational New Drug (IND) application for PCM-075, a Polo-like Kinase 1 (PLK1) inhibitor, for the treatment of Relapsed or Refractory (R/R) patients with Acute Myeloid Leukemia (AML).1

In most normal tissues, PLK1 is expressed at very low levels, however it has been found to be overexpressed in multiple AML cell lines and also in leukemia blasts from AML patients. Overexpression of PLK1 in AML patients have been reported to be associated with poor prognosis in these group of patients.2 PCM-075 selectively inhibits the PLK1 enzyme thereby inducing cell cycle arrest and apoptosis in cancer cells.3

The IND approval granted by the FDA allows PCM-075 to be evaluated in a phase Ib/II clinical trial which aims to evaluate the safety and efficacy of PCM-075 in combination with decitabine in patients with AML, who are in relapse or refractory.

  1. PR Newswire: Trovagene Announces FDA Approval of IND for Phase 1b/2 Trial of PCM-075 in Patients with Acute Myeloid Leukemia. 2017 Jul 27. http://www.prnewswire.com/news-releases/trovagene-announces-fda-approval-of-ind-for-phase-1b2-trial-of-pcm-075-in-patients-with-acute-myeloid-leukemia-300495015.html [Accessed 2017 Jul 28].
  2. Brandwein J. M. Targeting polo-like kinase 1 in acute myeloid leukemia. Ther Adv Hematol. 2015 Apr; 6(2): 80–87. DOI: 10.1177/2040620715571077.
  3. NCI Drug Dictionary: Polo-like kinase 1 inhibitor NMS-1286937.https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=660210 [Accessed 2017 Jul 28].

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
13 votes - 3 days left ...

Related articles

Newsletter

Subscribe to get the best content related to AML delivered to your inbox